

Supplementary Materials: Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer

Nadia Harbeck, Raquel von Schumann, Ronald Ernest Kates, Michael Braun, Sherko Kuemmel, Claudia Schumacher, Jochem Potenberg, Wolfram Malter, Doris Augustin, Bahriye Aktas, Helmut Forstbauer, Joke Tio, Eva-Maria Grischke, Claudia Biehl, Cornelia Liedtke, Sanne Lysbet De Haas, Regula Deurloo, Rachel Wuerstlein, Hans Heinrich Kreipe and Oleg Gluz




Figure S1. PD-L1 expression on IC and changes from baseline to Cycle 2. IC0, IHC staining on <1% of tumor area; IC1, ≥1% and <5%; IC2, ≥5% and <10%; IC3, ≥10%. IC, immune cells; IHC, immunohistochemistry; PD-L1, programmed death-ligand 1.




Figure S2. Association between *PIK3CA* mutation status and PAM50 subclass.




Figure S3. Association between *PIK3CA* mutation status and CD8 changes over time.



A**B****ADAPT HER2+/HR+**

Figure S4. (A) ADAPT Umbrella and (B) ADAPT HER2-positive/HR-positive trial designs (reproduced from Hofmann et al. 2013 [open access under CC license]) [48]. RS, recurrence score.